Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer

Pasqua, Anthony J. Di; Yuan, Hong; Chung, Youn‐Jee; Kim, Jin Ki; Huckle, James E.; Li, Chenxi; Sadgrove, Matthew P.; Trần, Thanh Huyền; Jay, Michael; Lü, Xiuling

doi:10.2967/jnumed.112.106609

Cited by 62 publications

(53 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though the authors could not clarify the mechanism of tumor uptake of 166 Ho-nanoparticle, such strategy might find utility in SPECT image-guided radiotherapy. The same group of authors further tested 166 Ho containing mesoporous silica nanoparticle in the same animal model and similar results were obtained (111). …”

Section: Carriers For Spect-igddsupporting

confidence: 56%

Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature

Chakravarty

Hong²,

Cai³

2015

CDT

View full text Add to dashboard Cite

Tremendous resources are being invested all over the world for prevention, diagnosis, and treatment of various types of cancer. Successful cancer management depends on accurate diagnosis of the disease along with precise therapeutic protocol. The conventional systemic drug delivery approaches generally cannot completely remove the competent cancer cells without surpassing the toxicity limits to normal tissues. Therefore, development of efficient drug delivery systems holds prime importance in medicine and healthcare. Also, molecular imaging can play an increasingly important and revolutionizing role in disease management. Synergistic use of molecular imaging and targeted drug delivery approaches provides unique opportunities in a relatively new area called `image-guided drug delivery' (IGDD). Single-photon emission computed tomography (SPECT) is the most widely used nuclear imaging modality in clinical context and is increasingly being used to guide targeted therapeutics. The innovations in material science have fueled the development of efficient drug carriers based on, polymers, liposomes, micelles, dendrimers, microparticles, nanoparticles, etc. Efficient utilization of these drug carriers along with SPECT imaging technology have the potential to transform patient care by personalizing therapy to the individual patient, lessening the invasiveness of conventional treatment procedures and rapidly monitoring the therapeutic efficacy. SPECT-IGDD is not only effective for treatment of cancer but might also find utility in management of several other diseases. Herein, we provide a concise overview of the latest advances in SPECT-IGDD procedures and discuss the challenges and opportunities for advancement of the field.

show abstract

Section: Carriers For Spect-igddsupporting

confidence: 56%

Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature

Chakravarty

Hong²,

Cai³

2015

CDT

View full text Add to dashboard Cite

show abstract

“…Nanoparticles also have the ability to deliver alternate cargo beyond standard chemotherapies, photosensitizers, and gene therapy constructs. Examples include the delivery of radio-isotopes for radionuclide therapy, 181 delivery of nitric oxide donors for eradication of cancer cells, 182 and using the intrinsic properties of nanoparticles for drug release, such as near-infrared triggered doxorubicin release from hollow gold nanoparticles. 183 …”

Section: Emerging Therapies and Future Directionsmentioning

confidence: 99%

Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics

2014

View full text Add to dashboard Cite

Ovarian cancer is the deadliest of all gynecological cancers and the fifth leading cause of death due to cancer in women. This is largely due to late-stage diagnosis, poor prognosis related to advanced-stage disease, and the high recurrence rate associated with development of chemoresistance. Survival statistics have not improved significantly over the last three decades, highlighting the fact that improved therapeutic strategies and early detection require substantial improvements. Here, we review and highlight nanotechnology-based approaches that seek to address this need. The success of Doxil, a PEGylated liposomal nanoencapsulation of doxorubicin, which was approved by the FDA for use on recurrent ovarian cancer, has paved the way for the current wave of nanoparticle formulations in drug discovery and clinical trials. We discuss and summarize new nanoformulations that are currently moving into clinical trials and highlight novel nanotherapeutic strategies that have shown promising results in preclinical in vivo studies. Further, the potential for nanomaterials in diagnostic imaging techniques and the ability to leverage nanotechnology for early detection of ovarian cancer are also discussed.

show abstract

“…For example, a lipophilic acetylacetonate complex of 165 Ho ( 165 Ho(AcAc) 3 ) was incorporated in commercial MCM-41 mesoporous silica nanoparticles (80-100 nm) and subsequently irradiated in a neutron flux to produce particles containing 166 Ho. 21 The holmium content in these nanoparticles was 17.8% + 1.4%. Holmium-166 containing mesoporous silica nanoparticles containing 20.8% + 1.9% was also reported for the treatment of non-small cell lung cancer.…”

mentioning

confidence: 95%

“…Previously, an acetylacetonate complex of holmium was incorporated with MCM-41 mesoporous silica nanoparticles, and these exhibited a radioactivity of 327.1 µCi/mg after neutron-activation in a thermal neutron flux of approximately 5.5 × 10 12 neutrons/cm 2 s for 2.2 h. 21 After administration of 110 µCi of these 166 Ho nanoparticles via intraperitoneal injection, tumors decreased in size in ovarian tumor-bearing mice; the total absorbed radiation dose in each tumor was estimated to be 135 Gy. 21 In humans, total doses of 45 to 80 Gy or higher are used. 59 Other examples of holmium nanoparticles exist.…”

mentioning

confidence: 99%

Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy

et al. 2014

Self Cite

View full text Add to dashboard Cite

Over the last decade, the development and application of nanotechnology in cancer detection, diagnosis, and therapy have been widely reported. Engineering of vehicles for the simultaneous delivery of chemo- and radiotherapeutics increases the effectiveness of the therapy and reduces the dosage of each individual drug required to produce an observable therapeutic response. We here developed a novel chemoradiotherapeutic 1,2-dioleoyl-sn-glycero-3-phosphocholine lipid coated/uncoated platinum drug loaded, holmium-containing, wrinkled mesoporous silica nanoparticle. The materials were characterized with TEM, FTIR, 1H NMR, energy dispersive x-ray, inductively coupled plasma-mass spectrometry, and zeta potential measurements. In vitro platinum drug release from both lipid coated and uncoated chemoradiotherapeutic wrinkled mesoporous silica are reported. Various kinetic models were used to analyze the release kinetics. The radioactivity of the chemoradiotherapeutic nanocarriers was measured after neutron-activation.

show abstract

Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer

Cited by 62 publications

References 17 publications

Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature

Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature

Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics

Chemoradiotherapeutic wrinkled mesoporous silica nanoparticles for use in cancer therapy

Contact Info

Product

Resources

About